Skip to main content
Top
Published in: Sleep and Breathing 3/2014

01-09-2014 | Original Article

Does CPAP therapy alter urinary albumin level in adult patients with moderate to severe obstructive sleep apnea syndrome?

Authors: Zehra Aşuk Yaşar, Zeynep Zeren Ucar, Ahmet Ugur Demir, Cenk Kirakli, Dilek Kalenci, Gültekin Tibet

Published in: Sleep and Breathing | Issue 3/2014

Login to get access

Abstract

Background

Urinary albumin is a marker of cardiovascular morbidity and mortality, and also it has been viewed as a marker for vascular endothelial dysfunction in both the kidneys and systemic vasculature. Lowering urinary albumin is associated with fewer cardiovascular and renal diseases. We investigated the change in urinary albumin after 1 month of continuous positive airway pressure (CPAP) therapy in obstructive sleep apnea syndrome (OSAS).

Methods

Eighteen patients (four females) in the middle-age group with moderate to severe OSAS were enrolled, who received and were compliant to CPAP therapy. Patients did not have a systemic disease or use a medication that could influence urinary albumin. Blood and urine samples were obtained in the morning after polysomnography and after 1 month of CPAP therapy to measure urinary albumin excretion and urinary albumin-to-creatinine ratio.

Results

Urinary albumin excretion (UAE) and urinary albumin/creatinine ratio (UACR) decreased significantly after 1 month of CPAP therapy: UAE at baseline and 1 month, 50 (1.1–174.8) and 22.7 (4.1–55.9); UACR, 27 (18.5–51.6) and 10.6 (4.3–43.1). UAE alteration was significantly associated with proportion of sleep time spent below an SaO2 of 90 %. Serum creatinine, serum total cholesterol, and creatinine clearance also decreased after 1 month of CPAP therapy.

Conclusion

Albuminuria is not rare in patients with OSAS and can be corrected after CPAP therapy. Determination of urinary albumin level is a simple, inexpensive, and noninvasive method that could be a promising biomarker to identify a high-risk population in patients with OSAS who may benefit from closer medical follow-up and preventive therapy.
Literature
1.
go back to reference Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, Steffes MW, Striker GE, Viberti GC (1995) Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346:1080–1084PubMedCrossRef Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, Steffes MW, Striker GE, Viberti GC (1995) Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346:1080–1084PubMedCrossRef
2.
go back to reference Hillege HL, Fidler V, Diercks GF, Van Gilst VH, de Zeuw D, van Veldhuısen DJ, Gans RO, Janssen WM, Grobbe DE, de Jong PE (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777–1782PubMedCrossRef Hillege HL, Fidler V, Diercks GF, Van Gilst VH, de Zeuw D, van Veldhuısen DJ, Gans RO, Janssen WM, Grobbe DE, de Jong PE (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777–1782PubMedCrossRef
3.
go back to reference Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, Jensen JS (2004) Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110:32–35PubMedCrossRef Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, Jensen JS (2004) Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110:32–35PubMedCrossRef
4.
go back to reference Abdelhafiz AH, Ahmed S, Nahas ME (2004) Microalbuminuria: marker or maker of cardiovascular disease. Nephron Exp Nephrol 119(suppl 1):e6–e10 Abdelhafiz AH, Ahmed S, Nahas ME (2004) Microalbuminuria: marker or maker of cardiovascular disease. Nephron Exp Nephrol 119(suppl 1):e6–e10
5.
go back to reference Quercioli A, Mach F, Montecucco F (2010) Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). Sleep Breath 14:261–269PubMedCrossRef Quercioli A, Mach F, Montecucco F (2010) Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). Sleep Breath 14:261–269PubMedCrossRef
6.
go back to reference Kinebuchi S, Kazama JJ, Satah M, Sakai K, Nakayama H, Yoshizawa H, Narita I, Suzuki E, Gejyo F (2004) Short-term use of continuous positive airway pressure ameliorates glomerular hyperfiltration in patients with obstructive sleep apnea syndrome. Clin Sci 107:317–322PubMedCrossRef Kinebuchi S, Kazama JJ, Satah M, Sakai K, Nakayama H, Yoshizawa H, Narita I, Suzuki E, Gejyo F (2004) Short-term use of continuous positive airway pressure ameliorates glomerular hyperfiltration in patients with obstructive sleep apnea syndrome. Clin Sci 107:317–322PubMedCrossRef
7.
go back to reference Ursavas A, Karadag M, Gullulu M, Demirdogen E, Coskun F, Onart S, Gozu RO (2008) Low-grade urinary albumin excretion in normotensive/non-diabetic obstructive sleep apnea patients. Sleep Breath 12:217–222PubMedCrossRef Ursavas A, Karadag M, Gullulu M, Demirdogen E, Coskun F, Onart S, Gozu RO (2008) Low-grade urinary albumin excretion in normotensive/non-diabetic obstructive sleep apnea patients. Sleep Breath 12:217–222PubMedCrossRef
8.
go back to reference Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B (2010) Elevated urinary albumin excretion with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 103:1869–1874CrossRef Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B (2010) Elevated urinary albumin excretion with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 103:1869–1874CrossRef
9.
go back to reference Diercks GF, van Boven AJ, Hillege JL, de Jong PE, Rouleau JL, van Gilst WH (2002) The importance of microalbuminuria as a cardiovascular risk indicator: a review. Can J Cardiol 18:525–535PubMed Diercks GF, van Boven AJ, Hillege JL, de Jong PE, Rouleau JL, van Gilst WH (2002) The importance of microalbuminuria as a cardiovascular risk indicator: a review. Can J Cardiol 18:525–535PubMed
10.
go back to reference Marin JM, Carrizo SJ, Vicente E, Agusti AG (2005) Long-term cardiovascular outcomes in men with obstructive sleep apnoea–hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365:1046–1053PubMedCrossRef Marin JM, Carrizo SJ, Vicente E, Agusti AG (2005) Long-term cardiovascular outcomes in men with obstructive sleep apnoea–hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365:1046–1053PubMedCrossRef
11.
go back to reference Daskalopoulou EG, Liavvas C, Nakas CT, Vlachogiannis EG, Bouros D, Dombros NV (2011) Obstructive sleep apnoea syndrome promotes reversal albuminuria during sleep. Sleep Breath 15:589–597PubMedCrossRef Daskalopoulou EG, Liavvas C, Nakas CT, Vlachogiannis EG, Bouros D, Dombros NV (2011) Obstructive sleep apnoea syndrome promotes reversal albuminuria during sleep. Sleep Breath 15:589–597PubMedCrossRef
12.
go back to reference Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y (2005) Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45:198–202PubMedCrossRef Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y (2005) Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45:198–202PubMedCrossRef
13.
go back to reference Halimi JM, Hadjadj S, Aboyans V, Allaert FA, Artigou JY, Beaufils M, Berrut G, Fauvel JP, Gin H, Nitenberg A, Renversez JC, Rusch E, Valensi P, Cordonnier D (2007) Microalbuminuria and urinary albumin excretion: French clinical practice guidelines. Diabetes Metab 33:303–309PubMedCrossRef Halimi JM, Hadjadj S, Aboyans V, Allaert FA, Artigou JY, Beaufils M, Berrut G, Fauvel JP, Gin H, Nitenberg A, Renversez JC, Rusch E, Valensi P, Cordonnier D (2007) Microalbuminuria and urinary albumin excretion: French clinical practice guidelines. Diabetes Metab 33:303–309PubMedCrossRef
14.
go back to reference Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869PubMedCrossRef Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869PubMedCrossRef
15.
go back to reference Lewis EJ, Hunsiaker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I (2001) Renoprotective effects of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 45:851–860CrossRef Lewis EJ, Hunsiaker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I (2001) Renoprotective effects of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 45:851–860CrossRef
16.
go back to reference Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206–1252PubMedCrossRef Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206–1252PubMedCrossRef
17.
go back to reference Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef
18.
go back to reference International classification of sleep disorders: diagnostic and coding manual. (2005). 2nd ed., American Academy of Sleep Medicine International classification of sleep disorders: diagnostic and coding manual. (2005). 2nd ed., American Academy of Sleep Medicine
19.
go back to reference Iber C, Ancoli-Israel S, Chesson AL, Quan SF (2007) The AASM manual for the scoring of sleep and associated events: rules, terminology, and technical specifications. American Academy of Sleep Medicine, Westchester Iber C, Ancoli-Israel S, Chesson AL, Quan SF (2007) The AASM manual for the scoring of sleep and associated events: rules, terminology, and technical specifications. American Academy of Sleep Medicine, Westchester
20.
go back to reference Hermida RC, Calvo C, Ayala DE, López JE (2005) Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension 46:960–968PubMedCrossRef Hermida RC, Calvo C, Ayala DE, López JE (2005) Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension 46:960–968PubMedCrossRef
21.
go back to reference American Diabetes Association (2004) Nephropathy in diabetes. Diabetes Care 579–583 American Diabetes Association (2004) Nephropathy in diabetes. Diabetes Care 579–583
22.
go back to reference Faulx MD, Isser AS, Kirchner HL (2007) Obstructive sleep apnea associated with increased urinary albumin excretion. Sleep 30(7):923–929PubMedCentralPubMed Faulx MD, Isser AS, Kirchner HL (2007) Obstructive sleep apnea associated with increased urinary albumin excretion. Sleep 30(7):923–929PubMedCentralPubMed
23.
go back to reference Herrera R, Almaguer M, Chipi J, Martínez O, Bacallao J, Rodríguez N, Abreu Mde L, Fariña O, Roche Mdel C (2010) Albuminuria as a marker of kidney and cardio-cerebral vascular damage. Isle of Youth Study (ISYS), Cuba. MEDICC Rev 12(4):20–26PubMed Herrera R, Almaguer M, Chipi J, Martínez O, Bacallao J, Rodríguez N, Abreu Mde L, Fariña O, Roche Mdel C (2010) Albuminuria as a marker of kidney and cardio-cerebral vascular damage. Isle of Youth Study (ISYS), Cuba. MEDICC Rev 12(4):20–26PubMed
24.
go back to reference Habbal R, Sekhri AR, Volpe M, i-Search Investigators (2010) Prevalence of microalbuminuria in hypertensive patients and its associated cardiovascular risk in clinical cardiology: Moroccan results of the global i-SEARCH survey—a sub-analysis of a survey with 21,050 patients in 26 countries worldwide. Cardiovasc J Afr 21(4):200–205PubMedCentralPubMed Habbal R, Sekhri AR, Volpe M, i-Search Investigators (2010) Prevalence of microalbuminuria in hypertensive patients and its associated cardiovascular risk in clinical cardiology: Moroccan results of the global i-SEARCH survey—a sub-analysis of a survey with 21,050 patients in 26 countries worldwide. Cardiovasc J Afr 21(4):200–205PubMedCentralPubMed
25.
go back to reference Kvenild K, Romundstad S, Midthjell K, Krüger O, Hallan H, Holmen J (2006) Microalbuminuria in treated hypertensives: only a mirror image of cardiovascular risk? The HUNT Study, Norway. Scand J Prim Health Care 24:145–153PubMedCrossRef Kvenild K, Romundstad S, Midthjell K, Krüger O, Hallan H, Holmen J (2006) Microalbuminuria in treated hypertensives: only a mirror image of cardiovascular risk? The HUNT Study, Norway. Scand J Prim Health Care 24:145–153PubMedCrossRef
26.
go back to reference Canales MT, Paudel ML, Taylor BC, Ishani A, Mehra R, Steffes M, Stone KL, Redline S, Ensrud KE (2011) Sleep-disordered breathing and urinary albumin excretion in older men. Sleep Breath 15(1):137–144PubMedCentralPubMedCrossRef Canales MT, Paudel ML, Taylor BC, Ishani A, Mehra R, Steffes M, Stone KL, Redline S, Ensrud KE (2011) Sleep-disordered breathing and urinary albumin excretion in older men. Sleep Breath 15(1):137–144PubMedCentralPubMedCrossRef
27.
go back to reference Chaudhary BA, Rehman OU, Brown TM (1995) Proteinuria in patients with sleep apnea. J Fam Pract 40:139–141PubMed Chaudhary BA, Rehman OU, Brown TM (1995) Proteinuria in patients with sleep apnea. J Fam Pract 40:139–141PubMed
28.
go back to reference Iliescu EA, Lam M, Pater J, Munt PW (2001) Do patients with obstructive sleep apnea have clinically significant proteinuria? Clin Nephrol 55:196–204PubMed Iliescu EA, Lam M, Pater J, Munt PW (2001) Do patients with obstructive sleep apnea have clinically significant proteinuria? Clin Nephrol 55:196–204PubMed
29.
go back to reference Casserly LF, Chow N, Ali S, Gottlieb DJ, Epstein LJ, Kaufman JS (2001) Proteinuria in obstructive sleep apnea. Kidney Int 60:1484–1489PubMedCrossRef Casserly LF, Chow N, Ali S, Gottlieb DJ, Epstein LJ, Kaufman JS (2001) Proteinuria in obstructive sleep apnea. Kidney Int 60:1484–1489PubMedCrossRef
30.
go back to reference Mello P, Franger M, Boujaoude Z, Adaimy M, Gelfand E, Kass J, Weisberg LS (2004) Night and day proteinuria in patients with sleep apnea. Am J Kidney Dis 44:636–641PubMedCrossRef Mello P, Franger M, Boujaoude Z, Adaimy M, Gelfand E, Kass J, Weisberg LS (2004) Night and day proteinuria in patients with sleep apnea. Am J Kidney Dis 44:636–641PubMedCrossRef
31.
go back to reference Busari O, Opadijo G, Olarewaju T, Omotoso A, Jımoh A (2010) Electrocardiographic correlates of microalbuminuria in adult Nigerians with essential hypertension. Cardiol J 17(3):281–287PubMed Busari O, Opadijo G, Olarewaju T, Omotoso A, Jımoh A (2010) Electrocardiographic correlates of microalbuminuria in adult Nigerians with essential hypertension. Cardiol J 17(3):281–287PubMed
32.
go back to reference Li J, Thorne LN, Punjabi NM, Sun CK, Schwartz AR, Smith PL, Marino RL, Rodriguez A, Hubbard WC, O’Donnell CP, Polotsky VY (2005) Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 97:698–706PubMedCrossRef Li J, Thorne LN, Punjabi NM, Sun CK, Schwartz AR, Smith PL, Marino RL, Rodriguez A, Hubbard WC, O’Donnell CP, Polotsky VY (2005) Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 97:698–706PubMedCrossRef
33.
go back to reference Robinson GV, Pepperell JC, Segal HC, Davies RJ, Stradling JR (2004) Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax 59:777–782PubMedCentralPubMedCrossRef Robinson GV, Pepperell JC, Segal HC, Davies RJ, Stradling JR (2004) Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax 59:777–782PubMedCentralPubMedCrossRef
34.
go back to reference Comondore VR, Cheema R, Fox J, Butt A, John Mancini GB, Fleetham JA, Ryan CF, Chan S, Ayas NT (2009) The impact of CPAP on cardiovascular biomarkers in minimally symptomatic patients with obstructive sleep apnea: a pilot feasibility randomized crossover trial. Lung 187:17–22PubMedCrossRef Comondore VR, Cheema R, Fox J, Butt A, John Mancini GB, Fleetham JA, Ryan CF, Chan S, Ayas NT (2009) The impact of CPAP on cardiovascular biomarkers in minimally symptomatic patients with obstructive sleep apnea: a pilot feasibility randomized crossover trial. Lung 187:17–22PubMedCrossRef
35.
go back to reference Steiropoulos P, Tsara V, Nena E, Fitili C, Kataropoulou M, Froudarakis M, Christaki P, Bouros D (2007) Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea–hypopnea syndrome. Chest 132:843–851PubMedCrossRef Steiropoulos P, Tsara V, Nena E, Fitili C, Kataropoulou M, Froudarakis M, Christaki P, Bouros D (2007) Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea–hypopnea syndrome. Chest 132:843–851PubMedCrossRef
36.
go back to reference Glassock RJ, Winearls C (2010) Diagnosing chronic kidney disease. Curr Opin Nephrol Hypertens 19:123–128PubMedCrossRef Glassock RJ, Winearls C (2010) Diagnosing chronic kidney disease. Curr Opin Nephrol Hypertens 19:123–128PubMedCrossRef
37.
go back to reference Burgos-Calderon R, Depine S (2010) Systematic approach for the management of chronic kidney disease: moving beyond chronic kidney disease classification. Curr Opin Nephrol Hypertens 19:208–213PubMedCrossRef Burgos-Calderon R, Depine S (2010) Systematic approach for the management of chronic kidney disease: moving beyond chronic kidney disease classification. Curr Opin Nephrol Hypertens 19:208–213PubMedCrossRef
38.
go back to reference Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D’Agostino RB, Vasan RS (2005) Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112:969–975PubMedCrossRef Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D’Agostino RB, Vasan RS (2005) Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112:969–975PubMedCrossRef
39.
40.
go back to reference Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS (2007) Prevalence of chronic kidney disease in the United States. JAMA 298:2038–2047PubMedCrossRef Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS (2007) Prevalence of chronic kidney disease in the United States. JAMA 298:2038–2047PubMedCrossRef
41.
go back to reference Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421–426PubMedCrossRef Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421–426PubMedCrossRef
Metadata
Title
Does CPAP therapy alter urinary albumin level in adult patients with moderate to severe obstructive sleep apnea syndrome?
Authors
Zehra Aşuk Yaşar
Zeynep Zeren Ucar
Ahmet Ugur Demir
Cenk Kirakli
Dilek Kalenci
Gültekin Tibet
Publication date
01-09-2014
Publisher
Springer Berlin Heidelberg
Published in
Sleep and Breathing / Issue 3/2014
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI
https://doi.org/10.1007/s11325-013-0914-4

Other articles of this Issue 3/2014

Sleep and Breathing 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.